Although there is increasing evidence of the protection offered by vaccination for pneumococcal disease, the majority of patients at risk in Europe are not vaccinated.
“Pneumonia is still a major health problem and a significant cause of mortality and morbidity worldwide,” said Prof. Antoni Torres (University Hospital Clinic Barcelona, Catalonia, Spain) . Streptococcus pneumoniae was the main cause of morbidity and mortality in the Global Burden of Disease Study . It contributed to more deaths than all other aetiologies combined in 2016 (1,189,937 deaths) .
Currently, two approved types of pneumococcal vaccines are available for adults: the pneumococcal polysaccharide vaccine (PPV)23 that contains a polysaccharide antigen and conjugate vaccines that contain polysaccharide antigens covariantly linked to a carrier protein. Pneumococcal conjugate vaccine (PCV)13, 10, and 7 belong to this group. The conjugate vaccines provide improved ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Taxi Drivers Exposed to Highest Levels of Black Carbon Pollution Next Article
Registry Confirms Nintedanib Efficacy under Real-life Conditions »
Table of Contents: ERS 2019
Holistic View on Asthma
Infectious Respiratory Disease: the Role of Vaccines
Interstitial Lung Disease
Best of the Posters
Novel Developments in Infectious Disease
A New Trial in Pulmonary Vascular Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.